Wedbush Starts Alexion Pharmaceuticals (ALXN) at Neutral
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Wedbush initiates coverage on Alexion Pharmaceuticals (NASDAQ: ALXN) with a Neutral rating and a price target of $132.00.
Analyst Heather Behanna commented, "We see Alexion as a pioneer in complement driven therapeutics. Although we expect to see continued growth in Soliris (eculizumab) sales over the next couple of years, in our view, clinical and regulatory risk surrounding pipeline expansion of eculizumab and competition on the horizon for PNH/aHUS suggests to us shares of Alexion are fairly valued at this time."
Shares of Alexion Pharmaceuticals closed at $133.69 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Finisar (FNSR) PT Raised to $44 at Needham & Company, Estimates Raised Sharply
- MKM Partners Raises Price Target on Ollie's Bargain Outlet (OLLI) Following 3Q
- Baird Raises Price Target on Itron (ITRI) to $73 After Meeting with Management
Create E-mail Alert Related CategoriesAnalyst Comments, New Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!